The key race: Moderna and BioNTech both clear a Phase 3 oncology bar within days of each other, while CRISPR's cardiovascular editing data lands at a cardiology congress rather than an oncology one
Biotech's two mRNA pioneers converted their oncology bets into real Phase 3 data within the same ten-day window in late August. Moderna and Merck announced on August 19 that the pivotal Phase 3 INTerpath-001 trial of intismeran autogene (mRNA-4157) plus KEYTRUDA met both its primary endpoint (recurrence-free survival) and key secondary endpoint (distant metastasis-free survival) in 1,137 patients with resected stage IIB-IV melanoma, the first positive Phase 3 result ever for an individualized mRNA neoantigen cancer therapy; Moderna shares surged as much as 90%-plus intraday and the companies plan to file for approval within months. BioNTech followed on August 20 by disclosing that its Phase 3 PRESERVE-003 trial of gotistobart in metastatic squamous non-small-cell lung cancer showed a clinically meaningful overall-survival benefit (hazard ratio of 0.46) against chemotherapy in patients who had already progressed on anti-PD-(L)1 therapy, with full data due at the World Conference on Lung Cancer in Seoul on September 12-15; the readout drove roughly a 23% BioNTech re-rating on oncology-pivot confidence. Both companies are proving the same point from opposite starting places: the mRNA platform that made its name on infectious-disease vaccines can now also clear an oncology Phase 3 bar, the harder proof point investors have been waiting for since both companies pivoted post-COVID.
Gene editing had its own notable week, on a different disease axis than usual. CRISPR Therapeutics presented late-breaking Phase 1a durability data for CTX310, its in vivo ANGPTL3 editing candidate, at the European Society of Cardiology Congress in Munich on August 28, showing a mean 79% reduction in circulating ANGPTL3 (max 89%) and a mean 48% reduction in triglycerides (max 78%), simultaneously published in the New England Journal of Medicine; the company is advancing CTX310 into Phase 1b trials in the US and abroad. That cardiovascular data landed the same week Vertex Pharmaceuticals, CRISPR's Casgevy partner, took the sector's sharpest legal setback: a US District Court for the District of Delaware ruled on August 24 that Lupin's proposed generic ivacaftor formulation does not infringe Vertex's patents on Kalydeco, a cystic fibrosis modulator, after the court found Lupin's 74% active-ingredient formulation fell outside Vertex's claimed 'about 80%' - the first real generic threat to reach a marketed Vertex CF modulator, clearing Lupin toward a launch with potential 180-day exclusivity pending FDA approval, though Vertex may still appeal.
Who's ahead: Vertex keeps widening into endocrinology even as one CF patent falls, and BioNTech's leadership handoff now has a real data catalyst behind it
Vertex remains the sector's most complete story despite the Lupin ruling, because Kalydeco is one modulator inside a broader Trikafta-led cystic fibrosis franchise that still drives the large majority of the company's roughly $11 billion in annual revenue, and because Vertex kept executing on its next act in parallel: its roughly $10 billion acquisition of endocrine-disease specialist Crinetics Pharmaceuticals cleared its last disclosed regulatory hurdles in mid-August (Hart-Scott-Rodino expiry August 12, Austrian, German and Australian antitrust clearances in hand), Crinetics shareholders voted on the deal August 28, and the companies still expect to close in early September 2026, adding the marketed acromegaly drug Palsonify plus a pipeline the companies say could add $5 billion or more in combined peak revenue. CRISPR Therapeutics, which keeps roughly 40% of Casgevy's economics, is diversifying in the same direction as Vertex: Casgevy itself is projected to nearly triple 2026 revenue to roughly $344 million combined (about $212 million to Vertex, $132 million to CRISPR) as more of its patient backlog completes treatment, while CTX310's new cardiovascular data and continuing Phase 1 dosing of CTX340 and CTX460 push the company's owned, non-Casgevy pipeline further along.
BioNTech is absorbing the summer's most consequential leadership change with a genuine data catalyst now behind it rather than ahead of it. Guido Oelkers, named CEO-designate August 3 to succeed founder Ugur Sahin no later than February 1, 2027, inherits a company whose late-stage oncology pipeline has grown past 25 Phase 2 and Phase 3 trials spanning immunomodulators (gotistobart), antibody-drug conjugates (trastuzumab pamirtecan, elfetabart drozuntecan) and mRNA cancer immunotherapies (autogene cevumeran), with the up-to-$11.1 billion Bristol Myers Squibb partnership for bispecific antibody BNT327 continuing to expand into a seven-trial pivotal program. Moderna and BioNTech are now converting on their respective oncology bets in the same month even as they run their own transitions on different tracks, Moderna toward its own 2028 cash-flow breakeven target, BioNTech toward a new chief executive inheriting a pipeline that just cleared its first pivotal lung-cancer survival benefit.
What decides it: whether payment infrastructure and AI-native pipelines can convert this year's data wins into revenue and clinical proof, not just headlines
Casgevy's slow real-world ramp remains the sector's clearest evidence that the constraint on gene and cell therapies is now payment infrastructure rather than science. CMS's Cell and Gene Therapy Access Model, which lets states negotiate outcomes-based deals for high-cost one-time therapies, had reached 33 states plus DC and Puerto Rico by 2026, covering roughly 84% of the Medicaid sickle-cell population, and roughly 90% of eligible US patients now have reimbursed insurance access; Casgevy generated $115.8 million in 2025 revenue and is modeled to grow toward roughly $344 million combined in 2026, a real acceleration but still a small fraction of what the $2.2 million list price times the roughly 60,000-plus eligible patients implies. Vertex's own Kalydeco setback adds a second dimension to the same question: even an approved, revenue-generating therapy can lose part of its protected market to a formulation dispute over a few percentage points of active ingredient, a reminder that regulatory approval and commercial durability are not the same test.
Whether AI-native drug discovery changes the industry's roughly 90% clinical failure rate, rather than just adding a better-funded way to fail at the same rate, remains unresolved and, if anything, further behind than the sector's own hype suggests. Google DeepMind's Isomorphic Labs has still not disclosed an actual clinical candidate despite Demis Hassabis's stated goal of trials by the end of 2026; Earendil Labs, which raised $787 million in March 2026, has an anti-TL1A antibody approaching Phase 2 but no pivotal data; and Xaira Therapeutics, still sitting on its record $1 billion launch round, has yet to disclose specific clinical-stage results. None of the wave of AI-native entrants attracting the sector's largest recent valuations has produced pivotal trial data, meaning the platforms priced as though they beat the odds have not yet had to prove it against the same bar Moderna, BioNTech and CRISPR just cleared with real Phase 1-3 readouts.
The money and the rules: M&A and IPOs keep compounding toward a record year, the Most-Favored-Nation roster holds at 17, and NIH's FY2027 number survives another round of proposed cuts
Capital kept arriving at a pace the sector has not sustained since before the pandemic. Biopharma M&A reached roughly $106 billion across 201 deals by early June 2026, putting the year on track to be the strongest for dealmaking since the pre-pandemic peak, driven by an approaching patent cliff (Merck's Keytruda, currently the world's best-selling drug, loses protection in 2028; Pfizer's Ibrance and Eli Lilly's Trulicity face 2027 exclusivity thresholds) that is pushing acquirers toward platform biotechs ahead of an estimated $200-236 billion of at-risk annual branded sales by decade's end. Twenty drug developers had gone public in 2026 as of this update, including five in August alone, with Kailera's April debut ($625 million) and Parabilis Medicines's later offering ($670 million) both setting new records for the largest biotech IPO ever; the XBI biotech index is up roughly 36% year-to-date and about 85% over the trailing twelve months, trading near 52-week highs.
Policy held roughly where it stood a month ago rather than moving further in either direction. The Trump administration's Most-Favored-Nation drug-pricing push remains at 17 signed manufacturer agreements, unchanged since Regeneron's April 23 deal, still covering the large majority of the branded US drug market and still reaching mainly Medicaid and cash-pay patients rather than commercial insurance or Medicare through the TrumpRx.gov platform. NIH funding cleared its next hurdle without a cut: the House Appropriations Committee's fiscal 2027 spending bill proposes $47.3 billion for NIH's base budget, a slight increase over fiscal 2026 and again well above the deep reductions the administration's budget request sought, though the House measure would also cap multi-year grant funding at 2025 levels and limit indirect-cost reimbursement to 30% at a small number of large-endowment institutions; Senate action on the bill remained pending as of this update.
What to watch through 2027
Watch Vertex close its roughly $10 billion Crinetics acquisition in early September 2026 following the August 28 shareholder vote, and watch whether Vertex appeals the Delaware ruling that cleared Lupin's generic Kalydeco or lets the 180-day exclusivity clock run. Watch Moderna and Merck file for melanoma-vaccine approval within months of the August 19 Phase 3 win, and watch BioNTech's full PRESERVE-003 overall-survival data land at the World Conference on Lung Cancer September 12-15 as Guido Oelkers's CEO handoff proceeds toward its February 1, 2027 deadline. Watch CRISPR Therapeutics advance CTX310 into Phase 1b following its ESC Congress data, and watch its CTX611 (SRSD107) Phase 2 topline and further zugo-cel readouts, both still guided to the second half of 2026.
Further out, watch whether Isomorphic Labs, Xaira or Earendil finally produce this wave's first pivotal AI-native clinical data, the event that would test whether generative drug discovery actually beats the industry's historical odds rather than just outraising it. Watch the next phase of the patent cliff arrive on schedule, Pfizer's Ibrance and Eli Lilly's Trulicity in 2027, Merck's Keytruda in 2028, and watch whether that timeline keeps pulling biopharma M&A toward a record year. On policy, watch whether the Most-Favored-Nation roster adds an 18th manufacturer or draws a serious legal challenge, and watch whether the Senate matches the House's $47.3 billion NIH number for fiscal 2027 or trims it back toward the administration's original request.
Sources
- Businesswire - Merck and Moderna announce Phase 3 INTerpath-001 trial met endpoints
- GlobeNewswire (BioNTech) - Late-stage lung cancer pipeline momentum at WCLC 2026
- Whalesbook - Lupin wins US court battle over Kalydeco patent claims
- GlobeNewswire (CRISPR Therapeutics) - Phase 1a data for CTX310 at ESC Congress 2026
- CNBC - Biotech M&A hits $106 billion, on track for best year since pre-Covid
- Science (AAAS) - House spending panel proposes slight raise for NIH in 2027
